胸腺五肽显著增强干扰素在抗病毒治程中的特异性CTL效应

被引：3

作者：

田洲

渠亚超

鲍旭丽

谢云

郭佳

闾军

机构：

[1] 首都医科大学附属北京佑安医院肝病与肿瘤生物治疗科

来源：

现代生物医学进展 | 2015年 / 15卷 / 07期

关键词：

慢性乙型肝炎; 胸腺五肽; 细胞毒性T淋巴细胞;

D O I：

10.13241/j.cnki.pmb.2015.07.016

中图分类号：

R512.62 [];

学科分类号：

摘要：

目的:探究在e抗原(HBe Ag)阳性的慢性乙型肝炎患者采用聚乙二醇干扰素-2a(peg-2a)联合核苷类药物治疗过程中,加用胸腺五肽对细胞免疫应答的影响。方法:选择采用聚乙二醇干扰素α-2a联合核苷类药物(拉米夫定+阿德福韦酯)治疗48周,HBe Ag仍为阳性,且HLA-A2阳性的慢性乙型肝炎患者18例,分为两组。一组原方案延长联合治疗作为对照,另一组在原方案基础上再加用胸腺五肽治疗(10 mg/次,2次/周,共24周)治疗,所有病人均治疗至96周。并做体外HBV特异性细胞毒T淋巴细胞(HBV specific CTL)培养增殖,通过Elispot技术分析其分泌细胞因子(肿瘤坏死因子-α,干扰素-γ,白介素-10)的功能。结果:HBe Ag转阴率,治疗96周时联合胸腺五肽组为44.4%(4/9),原方案对照组为22.2%(2/9)。HBs Ag滴度,48周时,HBs Ag为4571±3772 IU/m:;96周时,联合胸腺五肽组为1962±2869 IU/m L,转阴1人,原方案对照组为3490±3124 IU/m L,P=0.093。HBV特异性CTL培养增殖,96周时联合胸腺五肽组高于原方案对照组,且联合胸腺五肽组TNF-的分泌也高于原方案对照组,P<0.05。结论:胸腺五肽显著增强干扰素抗病毒治疗过程中的特异性CTL效应。

引用

页码：1259 / 1262

页数：4

共 13 条

[1]

Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B [J].

Chen, Yu ;

Li, Xuefen ;

Ye, Bo ;

Yang, Xianzhi ;

Wu, Wei ;

Chen, Baode ;

Pan, Xiaoping ;

Cao, Hongcui ;

Li, Lanjuan .

ANTIVIRAL RESEARCH, 2011, 91 (01) :23-31

[2]

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B [J].

Loggi, E. ;

Gramenzi, A. ;

Margotti, M. ;

Cursaro, C. ;

Galli, S. ;

Vitale, G. ;

Grandini, E. ;

Scuteri, A. ;

Vukotic, R. ;

Andreone, P. ;

Bernardi, M. .

JOURNAL OF VIRAL HEPATITIS, 2008, 15 (06) :442-448

[3]

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus [J].

Hilleman, MR .

VACCINE, 2003, 21 (32) :4626-4649

[4]

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B [J].

Boni, C ;

Penna, A ;

Bertoletti, A ;

Lamonaca, V ;

Rapti, I ;

Missale, G ;

Pilli, M ;

Urbani, S ;

Cavalli, A ;

Cerioni, S ;

Panebianco, R ;

Jenkins, J ;

Ferrari, C .

JOURNAL OF HEPATOLOGY, 2003, 39 (04) :595-605

[5]

Immunology of hepatitis B infection [J].

Jung, MC ;

Pape, GR .

LANCET INFECTIOUS DISEASES, 2002, 2 (01) :43-50

[6]

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy [J].

Boni, C ;

Penna, A ;

Ogg, GS ;

Bertoletti, A ;

Pilli, M ;

Cavallo, C ;

Cavalli, A ;

Urbani, S ;

Boehme, R ;

Panebianco, R ;

Fiaccadori, F ;

Ferrari, C .

HEPATOLOGY, 2001, 33 (04) :963-971

[7]

Thymosin α 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4 + CD8 + thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways 1 This work is supported; in part; by a grant from SciClone Pharmaceuticals; San Mateo; California; to M. Badamchian and a pre-doctoral fellowship from the Philip Morris Companies Inc. to C.A. Baumann. 1.[J].Christian A Baumann;Mahnaz Badamchian;Allan L Goldstein.Mechanisms of Ageing and Development.1997, 1

[8]

HBsAg定量与抗病毒治疗关系的研究进展 [J].

于乐成 ;

何长伦 ;

汪茂荣 .

传染病信息, 2013, 26 (04) :253-258

[9]

慢性乙型肝炎联合治疗专家共识.[J]..中国肝脏病杂志(电子版).2012, 01

[10]

胸腺五肽协同α-2b干扰素治疗慢性乙型肝炎临床体会 [J].

李长安 ;

庞盼姣 .

中国当代医药, 2010, 17 (33) :68-69

← 1 2 →